Table 5.
Multiple Sclerosis | Scorea | Neuromyelitis Optica | Scorea |
---|---|---|---|
Scheduled corticosteroids | 203 | Rituximab | 180 |
Pulse intravenous immunoglobulin | 189 | Pulse intravenous immunoglobulin | 163 |
Plasma exchange | 125 | Plasma exchange | 160 |
Natalizumab | 124 | Scheduled corticosteroids | 154 |
Cyclophosphamide | 119 | Azathioprine | 147 |
Azathioprine | 112 | Mycophenolate | 106 |
Mycophenolate | 109 | Cyclophosphamide | 99 |
Rituximab | 107 | Mitoxantrone | 64 |
Mitoxantrone | 82 | Natalizumab | 36 |
Respondents were asked to rank order their treatment preference given failure of first-preventive therapy. Scores consisted of the sum of all responses, with higher points given for preferred treatments.